臨床外科75巻9号

2020年09月発行

特集 変貌する肝移植—適応拡大・ドナー選択・治療戦略の最先端を知る

抗体関連型拒絶を巡るトピックス

抗体関連型拒絶反応に対する治療戦略—DSA，抗HLA抗体

著者： 大段秀樹¹ 井手健太郎¹ 大平真裕¹ 田原裕之¹ 谷峰直樹¹ 黒田慎太郎¹ 田中友加¹ 小林剛¹

所属機関： ¹広島大学大学院医系科学研究科消化器・移植外科学

ページ範囲：P.1084 - P.1090

文献概要

【ポイント】
◆preformed DSAもde novo DSAも肝グラフトの予後と関連する．
◆DSA陽性の無症候性T細胞性拒絶反応を特定することは，グラフト肝に炎症と線維化が進行している患者を同定することに有益である．
◆de novo DSAの発症リスク要因に，不十分なT細胞応答の制御は含まれる．

参考文献

1）Terasaki PI, Ozawa M：Predicting kidney graft failure by HLA antibodies：a prospective trial. Am J Transplant 4：438-443, 2004

2）Luque S, Lúcia M, Bestard O：Refinement of humoral immune monitoring in kidney transplantation：the role of “hidden” alloreactive memory B cells. Transpl Int 10：955-968, 2017

3）Shin BH, Everly MJ, Zhang H, et al：Impact of tocilizumab（qnti-IL-6R）treatment on immunoglobulins and anti-HLA antibodies in kidney transplant patients with chronic antibody-mediated rejection. Transplantation 104：856-863, 2020

4）Zhou W, Ohdan H, Tanaka Y, et al：NOD/SCID mice engrafted with human peripheral blood lymphocytes can be a model for investigating B cells responding to blood group A carbohydrate determinant. Transpl Immunol 12：9-18. 2003

5）Irei T, Ohdan H, Zhou W, et al：The persistent elimination of B cells responding to blood group A carbohydrates by synthetic group A carbohydrates and B-1 cell differentiation blockade：novel concept in preventing antibody-mediated rejection in ABO-incompatible transplantation. Blood 110：4567-4575, 2007

6）Tazawa H, Irei T, Tanaka Y, et al：Blockade of invariant TCR-CD1d interaction specifically inhibits antibody production against blood group A carbohydrates. Blood Oct 122：2582-2590, 2013

7）Campos EF, Tedesco-Silva H, Machado PG, et al：Post-transplant anti-HLA class Ⅱ antibodies as risk factor for late kidney allograft failure. Am J Transplant 6：2316-2320, 2006

8）Vo AA, Lukovsky M, Toyoda M, et al：Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 359：242-251, 2008

9）Auner HW, Beham-Schmid C, Dillon N, et al：The life span of short-lived plasma cells is partly determined by a block on activation of apoptotic caspases acting in combination with endoplasmic reticulum stress. Blood 116：3445-3455, 2010

10）Ide K, Tanaka Y, Sasaki Y, et al：A phased desensitization protocol with rituximab and bortezomib for highly sensitized kidney transplant candidates. Transplant Direct 1：e17. 2015

11）O'Leary JG, Kaneku H, Susskind BM, et al：High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection Postliver transplant. Am J Transplant 11：1868-1876, 2011

12）O'Leary JG, Kaneku H, Banuelos N, et al：Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation. Am J Transplant 15：1003-1013, 2015

13）Thomas KA, Valenzuela NM, Reed EF：The perfect storm：HLA antibodies, complement, FcγRs, and endothelium in transplant rejection. Trends Mol Med 21：319-329, 2015

14）Höfer A, Jonigk D, Hartleben B, et al：DSA are associated with more graft injury, more fibrosis, and upregulation of rejection-associated transcripts in subclinical rejection. Transplantation 104：551-561, 2020

15）Levitsky J, Kaneku H, Jie C, et al：Donor-specific HLA antibodies in living versus deceased donor liver transplant recipients. Am J Transplant 16：2437-2444, 2016

16）Del Bello A, Congy-Jolivet N, Danjoux M, et al：De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients. Transpl Int 28：1371-1382, 2015

17）Jucaud V, Shaked A, DesMarais M, et al：Prevalence and impact of de novo donor-specific antibodies during a multicenter immunosuppression withdrawal trial in adult liver transplant recipients. Hepatology 69：1273-1286, 2019